♨️ Debate at WCN26: Should complement inhibition be considered before targeted-release budesonide in patients with IgAN at risk of progression? A key discussion between upstream vs downstream treatment strategies in IgAN. 🧵(1) #ISNWCN #GlomerularDisease

#ISNWCN “KDIGO IgAN Session” discussing so interesting cases and perspectives 🇺🇸🇨🇳🇯🇵 🔎Effect of therapies on GFR loss and proteinuria 🎯Novel agents 👉🏻Disease activity and clinical background are important to determine appropriate therapy #GlomerularDisease #KidneyHealthMatters 🌎🫘🌸

“Understanding and Treating Complement-Mediated Glomerular Disease” #ISNWCN #ISGD ✅KPMP: right treatment, right person, right time 🧬Haplotype and Disease Penetrance- Genetic testing ❌C5b-9: more severe disease 🖊️C5a in AAV - complement therapies 🎯”RESET into homeostasis” #GlomerularDisease

🌟 Enjoying our #WCN2026 coverage? A heartfelt thank you to our incredible ISGD social media ambassadors, Dr. @gabyneph.bksy.social and Dr. Belén Gallegos, for bringing us the latest updates and insights in glomerular disease and keeping our community informed and engaged 🙌 #ISGD #GlomerularDisease

Applications are open for the next class of the #NephJC internship Apply here www.nephjc.com/news/nephjc-... or scan the QR code #ISNWCN

⛩️ Together in Yokohama at #ISNWCN with presidents of ERA, @theisn.org and @isgd.bsky.social ! ⛩️ @rosertorra.bsky.social, Marcello Tonelli, and @tobias-b-huber.bsky.social + Ron Gansevoort

At WCN’26, Tobias Huber highlighted the mission of the ISGD: uniting a 🌎 community to connect, educate, and advance research to improve care for patients with #GlomerularDisease With 1,700+ members across 102 countries, #ISGD is building a 🌎 network for innovation and collaboration in 🫘 disease

Heather Reich ISGD Chair of the Membership & Accreditation Committee, is present at the WCN’26 🤩 A great session about exploring the role of APRIL in IgAN 👉🏻 A great discussion of clinical scenarios #ISGD #GlomerularDisease #ISNWCN

Amazing! Paola Romagnani #ISGD #ISNWCN with “Podocytopathies: Knowns and Unknowns” 👉🏻Podocyte loss and regeneration 👀Autoimmune, genetic, adaptive, infectious, toxic, monoclonal 🎯Anti-slit autoantibodies-> ⬇️ prognosis #GlomerularDisease #Yokohama 🌸

Our ISGD president Tobias Huber is present at the WCN’26 🌸 👉🏻 His first session of the day: Kidney tissue-specific gene targeting 🦠 Adenovirus as a potential vector for gene targeting therapies #ISNWCN #GlomerularDisease #ISGD

🤔 Where is pathogenic IgA produced❓ 👉🏻 B cells induced in MALT can migrate to the bone marrow and differentiate into IgA-PC there 💉💊 We have emerging therapies to target B cells in Ivan but we still need a better understanding of the pathophysiology #ISNWCN @theisn.org

🤔 Where is pathogenic IgA produced❓ 👉🏻 B cells induced in MALT can migrate to the bone marrow and differentiate into IgA-PC there 💉💊 We have emerging therapies to target B cells in Ivan but we still need a better understanding of the pathophysiology #ISNWCN @theisn.org

🤔 What makes IgA pathogenic in IgAN❓ 👉🏻 A subgroup of GdIgA1with strong affinity for the glomerulus 🫘 💡 IgA type anti-MEsangial Cell Antibodies (Ig-MESCA) are GdIgA1-Ab. 🎯 Mesangial cells 🧫 Molecular mimicry with oral bacteria #ISNWCN @theisn.org

INShore Phase 3 trial: Obinutuzumab vs MMF in childhood-onset FRNS/SDNS to maintain remission 85 patients / 9 countries Type II anti-CD20 therapy → ⬇️ B-cell depletion Primary endpoint met: sustained remission at 52 wks significantly ⬆️ w/obinutuzumab #ISNWCN @ISNKidneycare

So interesting! “Cutting Edge Science in Nephrotic Syndrome/FSGS” #Yokohama #ISNWCN *Autoimmune Diseases treatments *B cell depletion - How broad? *Prognosis given by antibodies *Anti-human and anti-mouse CD39 antibodies Amazing treatment options #GLOMERULARDISEASE

"Finally in #Yokohama for 'Renal Pathology: Native Kidney Disease Pathology.' Covering IgG4-related disease, parasitic glomerular lesions, and genomics in Undeterminate Kidney Disease. Follow for more updates. #Nephrology #GlomerularDisease #Genomics

🤔 Do not know which session to attend in the WCN’26? @Tobias_B_Huber is giving this amazing session: 📌 Autoantibodies targeting podocyte-specific antigens in primary nephrotic syndrome 🗓️ Sunday, 29 March ⏰ 15:50 📍 304

👀 Attending the WCN’26? 👉🏻 Do not miss this interesting talk: 🐺 CAR-T cell therapy in lupus 🗓️ Monday, 30 Mar 2026 ⏰ 09:50 📍 301-302 Speaker: @BradRovin #ISNWCN @ISNKidneycare

Attention Fellows & Early Career Nephrologists! 🚀 🤓 10 scholarships (up to $1,500) are available for the RPA/ISGD Clinical Trial Bootcamp in Atlanta on April 16. Build your roadmap for research in private practice. ⏳ Apply (First-come, first-served): fk6zr.share-eu1.hsforms.com/2qgYbuOugRBm...

💡Join us for the RPA/ISGD Clinical Trials Bootcamp - designed for community nephrologists to establish robust research programs. Register here: bit.ly/RPA-ISGD-CTB Including: ✔️ Building the Business Plan & ROI ✔️ Executing the Plan ✔️ Support & Logistics ✔️ Strategies for varied practice settings

#ISGD Clinical Trial Bootcamp at the PNRC Fellows Workshop! 🚀 Equipping future investigators with practical steps to turn clinical trials into real-world care. Thanks to Vertex Pharmaceuticals for supporting this important mission! 👏 #Nephrology #ClinicalTrials #ISGD

#WorldKidneyDay is about more than raising awareness—it’s about raising expectations. New video with insights from @tobias-b-huber.bsky.social and Barbara Gillespie, MD, FASN and a preview of coming attractions at our Clinical Trials Summit! @hcplivenews.bsky.social www.hcplive.com/view/clinica...

💥🎙️ Its a DOUBLE FEATURE: GN in Ten x @nephmadness.bsky.social The wait is over. We’re dropping two high-powered episodes to get your brackets ready. Whether you're fighting autoantibodies or the complement cascade, our experts have the breakdown you need! 🦸‍♂️🦸‍♀️ @nkf-professionals.bsky.social #ISGD

#NephMadness 2026: The PodCrawl Featuring these podcasts: - GN in Ten @isgd.bsky.social - Global Kidney Care @theisn.org - @freelyfiltered.bsky.social - @febrilepodcast.com - Kidney Commute @nkf-professionals.bsky.social - @coreimpodcast.bsky.social - Nephron Segment bit.ly/NM26Podcrawl

On #RareDiseaseDay & every day, we're uniting a global community to connect, educate, transform, and support GD research and medicine to improve patient care! PS: FDA wants feedback on their rare disease educational materials…more info here eu1.hubs.ly/H0s9nst0

✈️So many kidney conferences, so little time...Wondering which to attend? Trying to plan a meeting that won't conflict? We have the solution! Our GD Calendar has all the #kidneymeetings info in one subscribable place 📅 You're welcome 😊 www.is-gd.org/calendar-of-...

10K downloads for #GNin10! 🥳 📈 Congratulations to our hosts @kdjhaveri.bsky.social & Dr. Koyal Jain for their incredible work & dedication to glomerular disease education. 🧬 🎧 Listen here: gninten.transistor.fm 👀 Stay tuned: Special #NephMadness episodes coming early March! 🏀 #NephTwitter #ISGD

ISGD Clinical Trial Bootcamp @ the ASPN-PNRC Fellows Workshop! 🩺🔬🌴 We’re bridging the research gap by: ✅ Equipping next-gen investigators ✅ Expanding the trial-ready workforce ✅ Making trials a standard of care 🔗 www.is-gd.org/time-to-trai... #Nephrology #ClinicalTrials #ISGD #PNRC

🚀🌴💊 Early Bird Registration and abstract submissions are now OPEN for the 2026 ISGD Clinical Trials Summit in Galveston, TX! Join us in Nov. to advance innovative kidney research, find solutions to glomerular disease challenges, and shape the future of clinical trials. www.is-gd.org/cts-2026-reg...

Join our Clinical Trials Summit in Galveston, TX (Nov 13-15 2026) to advance innovative solutions in rare kidney disease trials. Registration & abstracts open Monday! www.is-gd.org/2026-cts @tobias-b-huber.bsky.social @utmbhealth.bsky.social Dr. Shikha Wadhwani Dr. Jochen Reiser

🚨New GN in 10: Everything you need to know about ANCA Vasculitis🎙️ Join @kdjhaveri.bsky.social & Dr. Koyal Jain for a high-yield Board Review session covering all the basics and recent advances: share.transistor.fm/s/8be7fb84 #NephTwitter #MedEd #Vasculitis #BoardPrep @tobias-b-huber.bsky.social

The future of nephrology research is here! 🚀 ISGD Clinical Trial Bootcamps go global in 2026! 📍 Miami, Atlanta, Bordeaux & Mar de Plata. 🎟 Register for PNRC/RPA now: www.is-gd.org/time-to-train #ISGD #ESPNSociety #PNRC @renalphysicians.bsky.social @alanepe.bsky.social @tobias-b-huber.bsky.social

The International Society of Glomerular Disease is pleased to welcome Barbara Gillespie, MD, MMS, FASN, into the advisory role of Chief Medical and Strategy Officer! 🥳 @tobias-b-huber.bsky.social www.is-gd.org/en/news-from...

ASN has shown us the incredible advances being made in glomerular diseases and the opportunities we have to continue improving glomerular science, medicine, and patient care! Join the movement at www.is-gd.org/en/join-isgd #ISGD #GlomerularDisease #ASNKidneyWeek2025 @tobias-b-huber.bsky.social

Post-ASN, the ISGD team visited Galveston and the UTMB campus and team! We chose the venue for the Inaugural 2026 ISGD Clinical Trials Summit. Please save the date: November 12-16, 2026. Stay tuned for more updates on this landmark event! #ClinicalTrials #ISGD @tobias-b-huber.bsky.social

🌐 Building Our Network - Our ASN reception was a massive success, bringing together over 200 people! It is amazing to see the network we have formed in under three years. It was fantastic to connect with so many of you. #ASN2025 #ISGD #KidneyWeek2025 @tobias-b-huber.bsky.social

Congrats to ISGD Members @ksusztak.bsky.social, @rkramann.bsky.social , Laura Mariani, and @genetickidneydoc.bsky.social on receiving major ASN awards! And congratulations to ISGD members who contributed to this year's amazing scientific content 💡#ISGD #KidneyWeek2025 @tobias-b-huber.bsky.social

ISGD had an impactful week at ASN 2025. Big Shout out to Matthias Kretzler ISGD Steering Committee Member and ASN Program Co-Chair, for his leadership in shaping the conference, and for keeping GD at the forefront #ISGD #ASN2025 #GlomerularDisease #KidneyWeek2025 @tobias-b-huber.bsky.social

Importance of surrogate endpoints - focus on Proteinuria! @ASNKidney ▶️ Proteinuria and Podocyte loss mechanisms 🐙 ▶️ Accelerated drug approval 🚀 ▶️ A call to Action! by @kirkcampbell - PARASOL results and future expansion 🌟 #KidneyWk #ISGDTweets #GlomerularDisease

Oral Abstract Session 🌟 ▶️ The greater the reduction in Proteinuria, the better the outcomes in IgA Nephropathy! 🔑 ▶️ Outcomes across diseases and age in the CureGN cohort! 👏 #KidneyWk #ISGDTweets #GlomerularDisease

Outstandining talk by @AstridWeins on anti-nephrin antibodies ▶️ Anti-nephrin Ab provides diagnostic value, guide treatment and define prognosis ▶️ Refined techniques and appropriate treatment-related timing measurement is crucial 🧪 #KidneyWk #ISGDTweets #GlomerularDisease

Innovative initiatives in Pediatric NS! ▶️ PARASOL provides a regulatory path for new drugs by proving proteinuria as a marker 🌟 and is expanding to APOL-1-mediated KD and MN! 🚀 ▶️ NEPTUNE Match moving towards personalized medicine 🎯 #KidneyWk #ISGDTweets #GlomerularDisease

Pediatric Nephrotic Syndrome Translational Session ▶️ Diverse Immunological Architecture! ▶️ Recent focus on novel autoantibodies 🎯 ▶️ GWAS + composite HLA-PRS in the search of a unified disease mechanism 🧬 #KidneyWk #ISGDTweets #GlomerularDisease

B-cell depleting strategies in lupus nephritis 🐺 ▶️ Obinutuzumab confers higher complete remission rates vs other mAbs ▶️ Immunological reset 🆕 CAR-T cells - deeper depletion in varied differentiation stages (for refractory cases!) #KidneyWk #ISGDtweets #GlomerularDisease

The role of B-cells in lupus nephritis by @AugustoVaglio 🐺 ▶️ B-cell activation and expanison ▶️ B-cell overdifferentiation and hiperreactivity ▶️ Isolated germinal centers #KidneyWk #ISGDtweets #GlomerularDisease

Thrombotic microangiopathy in children - extensive differential @SethiRenalPath! ▶️ From STEC-HUS, TTP to atypical HUS genetics! 🧬 ▶️ C3G and DDD involve distinct complement components - ApoE! ▶️ Searching for aHUS specific markers 🔍 #KidneyWk #GlomerularDisease

Membranous Nephropathy is not Adult-exclusive #ASN2025! ▶️ Pediatric patients are not 'little adults' @JeanHouMD - different clinical profiles, many unknown antigens! 🌟 ▶️ Hot insights into new pediatric MN antigens @SethiRenalPath - Poster Pearls 👀 #GlomerularDisease

Yesterday's highlights: IgA Nephropathy at Plenary Session! ▶️ 1. Impact of new tools by Dr. Vlado Perkovic - first #ASN2025 publication @kidneyint.bsky.social! 🔥 ▶️ 2. Just published @nejm.org - Dr. Richard Lafayette on the ORIGIN 3 trial: Atacicept led to remarkable results! 🤯 #GlomerularDisease

Spreading the word about the Importance and Power of Podocytes at @asnkidney.bsky.social Kidney Week in Houston. @isgd.bsky.social

ASN begins with an inspiring speech from Dr. Prabir Roy-Chaudhury, ASN president. A standing ovation for the new landscape of clinical trials in GD. ISGD is on the ground and will be reporting on the latest in GD. Follow and join the conversation. #ASN2025 #GlomerularDisease